Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Finch Therapeutics Group, Inc. (FNCH : OTC)

• Company Description    Finch Therapeutics Group Inc. is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery(R) platform to develop a novel class of orally administered biological drugs. The company's product candidate includes CP101, FIN-211, FIN-524 and FIN-525. Finch Therapeutics Group Inc. is based in SOMERVILLE, Mass. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $13.49 Daily Weekly Monthly 20 Day Moving Average: 2,079 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 1.17 52 Week High: $16.10 52 Week Low: $10.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.98% -0.81% 12 Week 11.00% 9.21% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 75 State Street Suite 100 - Boston,MA 02109 USA ph: 617-229-6499 fax: - ir@finchtherapeutics.com http://www.finchtherapeutics.com

• General Corporate Information    Officers Matthew P. Blischak - Chief Executive Officer; President and Secretary Susan Graf - Chairman Lance Thibault - Chief Financial Officer Domenic Ferrante - Director Chris Shumway - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 31773D200 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: 04/22/26 Share - Related Items Shares Outstanding: Most Recent Split Date: 6.00 (0.03:1) Beta: 1.17 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/22/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.52 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - - 06/30/25 - - Current Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - - Quick Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - - Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - - Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©